NEFL and proximal spinal muscular atrophy: A separate study evaluated serum NfL as a biomarker in 18 pediatric patients with SMA undergoing nusinersen treatment, and established age-specific reference values using Single Molecule Array (SIMOA) technology from 97 healthy controls (Nitz et al. [44]).